Manning & Napier Advisors LLC Invests $10.82 Million in Bristol Myers Squibb Company $BMY

Key Points

• Manning & Napier Advisors initiated a $10.82 million position in Bristol Myers Squibb, buying 184,742 shares during the second quarter. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb exceeded quarterly expectations with $2.04 in adjusted EPS versus the $1.60 consensus and $12.97 billion in revenue, up 5.7% year over year. The company also pays a quarterly dividend of $0.63, representing a 3.7% annualized yield.
• Analyst sentiment remains positive overall, with a consensus rating of “Moderate Buy” and a $66.06 target price, although ratings range from “Strong Buy” to “Sell.” Shares recently opened at $67.30, near their 12-month high of $68.64.

Manning & Napier Advisors LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 184,742 shares of the biopharmaceutical company's stock, valued at approximately $10,818,000.

Other hedge funds also recently modified their holdings of the company. Swiss RE Ltd. bought a new stake in Bristol Myers Squibb during the fourth quarter worth about $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Physician Wealth Advisors Inc. boosted its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb in the second quarter valued at approximately $27,000. Finally, Bayban acquired a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $31,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $67.30 on Tuesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The business has a 50-day simple moving average of $60.77 and a two-hundred day simple moving average of $59.47. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The stock has a market cap of $137.47 billion, a PE ratio of 14.82, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business's revenue for the quarter was up 5.7% on a year-over-year basis. During the same period last year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. Bristol Myers Squibb's payout ratio is currently 55.51%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BMY shares. Raymond James Financial started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "strong-buy" rating on the stock. Wall Street Zen upgraded Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 target price on the stock in a research report on Wednesday, August 5th. Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the stock an "equal weight" rating in a report on Friday, July 31st. Finally, UBS Group downgraded shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.